Has Intekhab Ahmed, MD received payments from drug or device companies?

Yes. Drug and device makers reported $925,836 in general payments to Intekhab Ahmed, MD across 1,614 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Intekhab Ahmed, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Intekhab Ahmed, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Intekhab Ahmed, MD

Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1760406961

Payments from drug & device makers

$925,836in general payments, 2019–2025

Across 1,614 payments — averaging $573.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$213K
Lilly USA, LLC$205K
AstraZeneca$147K
Ascendis Pharma Endocrinology Inc$105K
Takeda Pharmaceuticals U.S.A., Inc.$52K
Chugai Pharmaceutical Co., Ltd.$46K
plus $158K from 45 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	719	$212,990
Lilly USA, LLC	374	$204,659
AstraZeneca(2 entities)	52	$147,456
Ascendis Pharma Endocrinology Inc	41	$104,826
Takeda Pharmaceuticals U.S.A., Inc.	38	$51,600
Chugai Pharmaceutical Co., Ltd.	2	$46,133
Amryt Pharma Holdings Ltd	39	$34,640
Shire North American Group Inc	15	$28,092
Chiesi USA, Inc.	23	$27,099
Boehringer Ingelheim	42	$21,735
Sanofi-aventis U.S. LLC	9	$12,251
Astrazeneca UK Limited	1	$9,061
Amgen(2 entities)	75	$7,252
Seagen Inc.	2	$5,500
Sanofi US Services Inc.	3	$4,980
Chiasma, Inc.	2	$2,660
Ultragenyx Pharmaceutical Inc.	3	$1,496
Amarin Pharma, Inc.	37	$508
Abbott	23	$473
Corcept Therapeutics	15	$348
Radius Health, Inc.	18	$335
Xeris Pharmaceuticals, Inc.	10	$217
Amneal Pharmaceuticals LLC	11	$194
Pfizer	8	$160
Amphastar Pharmaceuticals, Inc.	7	$126
Mannkind Corporation	2	$119
AbbVie	5	$114
Recordati_rare_diseases_inc.	5	$95
Foundation Medicine, Inc.	1	$91
Neurocrine Biosciences, Inc.	3	$79
Esperion Therapeutics, Inc.	5	$77
Ipsen Biopharmaceuticals, Inc	3	$53
Bayer	2	$41
Alvogen Inc	2	$33
Madrigal Pharmaceuticals	1	$33
Dexcom, Inc.	1	$29
Ascensia Diabetes Care US Inc.	1	$26
BETA Bionics, Inc.	1	$23
Almatica Pharma LLC	1	$23
Novartis	1	$23
Tandem Diabetes Care, Inc.	1	$22
Medtronic	1	$20
Kyowa Kirin, Inc.	1	$19
Tolmar, Inc.	1	$19
Azurity Pharmaceuticals, Inc.	1	$17
GRT US Holding, Inc.	1	$17
Rhythm Pharmaceuticals, Inc.	1	$17
Clarus Therapeutics Inc.	1	$16
Acerus Pharmaceuticals Corporation	1	$15
IBSA Pharma Inc.	1	$14
Vistapharm, Inc.	1	$12

How this compares

$925,836 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$77,962

Medicare patients

425

Services billed

853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Philadelphia

Mona Al MukaddamPhiladelphia$3.9M
Serge JabbourPhiladelphia$3.1M
Mihaela BiscoveanuPhiladelphia$1.5M
Barbara SimonPhiladelphia$1M
Mitchell LazarPhiladelphia$1M
Jane MayrinPhiladelphia$628K
Michael RickelsPhiladelphia$606K
Steven NagelbergPhiladelphia$483K
Kevin WilliamsPhiladelphia$137K
Laura YoungPhiladelphia$99K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →